Self-reported adherence and pharmacy refill adherence are both predictive for an undetectable viral load among HIV-infected migrants receiving cART by Been, S.K. (Sabrina) et al.
RESEARCH ARTICLE
Self-reported adherence and pharmacy refill
adherence are both predictive for an
undetectable viral load among HIV-infected
migrants receiving cART
Sabrina K. Been1☯*, Elif Yildiz1,2☯, Pythia T. Nieuwkerk3‡, Katalin Poga´ny4‡, David A. M.
C. van de Vijver5‡, Annelies Verbon1,2☯*
1 Department of Internal Medicine, division of Infectious Diseases, Erasmus University Medical Center,
Rotterdam, The Netherlands, 2 Department of Medical Microbiology and Infectious Diseases, Erasmus
University Medical Center, Rotterdam, The Netherlands, 3 Department of Medical Psychology, Academic
Medical Center, Amsterdam, The Netherlands, 4 Department of Internal Medicine, Maasstad Hospital,
Rotterdam, The Netherlands, 5 Viroscience department, Erasmus University Medical Center, Rotterdam,
The Netherlands
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work
* s.been@erasmusmc.nl (SB); a.verbon@erasmusmc.nl (AV)
Abstract
HIV-infected migrants were shown to have poorer treatment outcomes than Dutch HIV-
infected patients, often due to worse treatment adherence. Self-reported adherence would
be an easy way to monitor adherence, but its validity relative to pharmacy refill adherence
has not been extensively evaluated in migrants. All HIV-infected migrants older than 18
years and in care at the two Rotterdam HIV-treatment centers were eligible. Refill data with
leftover medication (PRL) (residual pill count) were obtained from their pharmacies up to 15
months prior to inclusion. Self-reported adherence to combination Antiretroviral Therapy
was assessed by four questions about adherence at inclusion. Additionally, risk factors for
pharmacy refill non-adherence were examined. In total, 299 HIV-infected migrants were
included. Viral load (VL) was detectable in 11% of the patients. Specificity of PRL was 53%
for patients with an adherence of 100% and decreased with lower cut-off values. Sensitivity
and negative predictive value (NPV) were 68% and 15% and increased with lower cut-off
values. Positive predictive value (PPV) was around 93% for all cut-off values. Using the self-
reported questions, 139 patients (47%) reported to be adherent. Sensitivity was 49% and
specificity was 72%. PPV and NPV were 95% and 13%. No risk factors for pharmacy refill
non-adherence were found in multivariable analyses. Both PRL and self-reported adher-
ence, can predict undetectable VL in HIV-infected migrants. PPV and NPV are similar for
both methods. This study shows that using four self-reported items is sufficient to predict
adherence which is crucial for optimal clinical outcome in HIV-infected migrants.
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Introduction
Treatment adherence is one of the strongest predictors of virological failure, development of
drug resistance, disease progression and death [1]. Poor adherence to combination antiretrovi-
ral therapy (cART) is common in both developing and developed nations. It was found in
around 20% of HIV-infected patients in Africa and in around 14% in the United Stated of
America [2–4]. It is not clear what the influence of migration from developing countries to
developed countries is on adherence and outcome. In Europe, migrant people living with HIV
(MPLWH) have worse treatment outcomes than non-migrant patients living with HIV [5–9].
Although lack of adherence could not be demonstrated as a reason for virological failure in
one study [6], factors associated with poor adherence such as younger age, high alcohol con-
sumption, presence of psychiatric co-morbidity, stigma, lack of self-efficacy or social support
are frequently found in migrants [6, 10, 11]. With the strongly increasing migration from
Africa and the Middle East to Europe it is pivotal to determine adherence levels with the goal
to intervene when adherence is poor in order to improve treatment outcome in MPLWH.
Treatment adherence of HIV-infected patients can be measured in several ways. Pharmacy
refill data have been shown to be a useful tool in both developing and developed nations [2,
12–14]. Calculation of pharmacy refill adherence is most practical in closed pharmacy systems
where information about dispensed medication can be retrieved from a single registry. In the
absence of a closed pharmacy system, calculation of pharmacy refill adherence is more labori-
ous because information retrieved from different pharmacies need to be combined. Although
pharmacy refill data are valuable on a population level, it seems to be less suitable to measure
adherence on an individual patient level. Self-reported adherence questions, administered
either via questionnaires or via interviews, have previously been shown to be a practical adher-
ence assessment method [6, 14]. However, it is well established that self-reports may overesti-
mate adherence levels compared with more objective measures, which is attributed to recall
bias and social desirability bias [15]. The validity of self-reported adherence questions adminis-
tered among MPLWH in Europe might be influenced by cultural differences. This could facili-
tate social desirability bias.
Since retention in care and treatment adherence are crucial for a good outcome in HIV-
infected patients [12, 16], and MPLWH were previously shown to have worse HIV treatment
outcomes and adherence levels, valid and practical adherence measures are needed to identify
persons in need of additional adherence support. We therefore assessed two methods, phar-
macy refill adherence and self-reported adherence, in order to determine their comparative
predictive value for undetectable viral load in a large group of MPLWH from different geo-
graphical origins. In addition, we examined risk factors for non-adherence based on pharmacy
refill data calculation.
Methods
Study population
Patients included in the ROtterdam ADherence (ROAD) project, a study aiming to increase
adherence in first and second generation adult immigrant people living with HIV (The Neder-
lands National Trial Register Number (NTR)—NTR4941) were recruited at outpatient clinics
in the two Rotterdam HIV treatment centers (Erasmus University Medical Center and Maas-
stad Hospital) between November 2012 and July 2013 [11]. In these HIV treatment centers,
52% of the PLWH in care in 2014 were first generation immigrants (data not shown). Partici-
pants had to be sufficiently fluent in at least one of the following languages: Dutch, English,
French, Spanish, or Portuguese.
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the Dutch Aids Fonds to perform the study. This
does not alter our adherence to PLOS ONE policies
on sharing data and materials.
This study focuses on a sub population of the 352 patients included in the ROAD project.
Patients using cART for >6 months prior to inclusion signed informed consent allowing the
investigators to consult their pharmacies about medication refills and to check the patients’
medical files for information about the prescribed start and stop of cART regimens, and viral
load results. Additional relevant clinical and socio-demographic characteristics, and psychoso-
cial variables were collected via an interviewer administered questionnaire [11]. An undetect-
able viral load (VL) was defined as HIV-1 RNA or HIV-2 RNA <50 copies/ml.
The study was approved by the Institutional Review Boards of the Erasmus University Med-
ical Center and the Maasstad Hospital, Rotterdam.
Study design and data collection
Collecting pharmacy refill data. In the Netherlands, there is no closed pharmacy system.
Therefore, names of the pharmacies from which antiretroviral medication was collected were
given by the participants when they attended the outpatient clinic for a routine visit. In the
Netherlands, patients who are stable on cART usually collect their antiretroviral drugs at the
pharmacy every 90 days. Pharmacy refill data was collected at one time point. We sent a fax to
each patient’s pharmacy to ask for information regarding the type of antiretroviral medication,
pills supplied, prescribed daily dose, date of supply up to 15 months prior to inclusion. A copy
of the signed informed consent was provided along with the request. Reminders per email and
fax were sent and if necessary, pharmacies were contacted by telephone.
Pharmacy refill adherence calculation. For our analyses, we assumed that medication
was taken as prescribed until the supply was finished. Calculation of adherence with pharmacy
refill data was done taking leftover medication (residual pill count) into account, a method
that substantially limits misclassification of adherence [13]. In short, a period of 3 months
prior to inclusion (90 days) was used as the episode to monitor adherence. Pharmacy refill
adherence was calculated by determining the average supply percentage of all cART during
this 90 days episode. The 12 months (360 days) prior to this episode were used to calculate the
leftover medication. Antiretroviral regimen changes were taken into account. For the calcula-
tion of leftover medication, we assumed that patients had leftover medication if medication
was refilled while the number of pills dispensed at a former refill divided by the prescribed
daily doses and multiplied by the days since the previous refill was higher than zero, except
when the patient changed his or her regimen. The residual number of pills was rolled over to
the next refill period leading to the following formula for pharmacy refill adherence with left-
over medication:
Pharmacy refill adherence when leftover medication is includedðPRLÞ ð%Þ ¼
Leftover medication from previous refillsþ Collected medication at refill
Days between two refills Daily dose
 
 100
If the supply of pills for a refill period extended beyond the 90-day episode or the date of a
switch, we truncated adherence at 100%. Additionally, we investigated the number of patients
who would be misclassified as ‘non- adherent’ when leftover medication was not taken into
account, using the following formula to determine pharmacy refill adherence:
Pharmacy refill adherence when leftover medication is not includedðPRÞ ð%Þ ¼
Collected medication at refill
Days between two refills  Daily dose
 
 100
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Self-reported adherence. Self-reported adherence was measured by four items via an
interviewer administered questionnaire at the day of inclusion. The questionnaire was avail-
able in 4 languages: Dutch, English, French, and Spanish. The first two items measured recol-
lection of adherence: Q1: ‘Thinking about the past four weeks, how would you rate your ability
to take all your medications as your doctor prescribed them?’ (6-point Likert scale ranging
from 1 = ‘very poor’ to 6 = ‘excellent’) and Q2: ‘Thinking about the past four weeks, how often
did you take all your HIV antiretroviral medications as your doctor prescribed them?’ (5-point
Likert scale ranging from 1 = ‘none of the time’ to ‘all of the time) [17]. Item three measured
the adherence over the past week: Q3: ‘How many days in the past week did you take all anti-
HIV medicines that were prescribed?’ (‘5-point Likert scale ranging from 1 = ‘not on day’ to
5 = ‘all 7 days’) [15, 18, 19]. The last item measured the most recent missed dose: Q4: ‘When
was the last time you missed any of your anti- HIV medications?’ (6-point Likert scale ranging
from 1 = ‘ within the past week’ to ‘never missed’ [20]. For the calculation of adherence, a
patient was classified as ‘adherent’ if they had the following answers:
- Q1: ‘very good’ or ‘excellent’
- Q2: ‘all of the time’
- Q3: ‘all 7 days’
- Q4: ‘more than three months ago’, ‘never missed’ or ‘I’m not sure’
Data and statistical analysis
Chi2 and Fisher-Exact tests were used to compare categorical data between groups and T-tests
and Mann-Whitney tests for continuous data. For each adherence calculation we calculated
specificity (i.e., percentage of patients with detectable VL which is identified as non-adherent),
sensitivity (i.e., percentage of patients with undetectable VL which is identified as adherent),
negative predictive value (NPV) (i.e., percentage of non-adherent patients that has a detectable
VL), and positive predictive value (PPV) (i.e., percentage of adherent patients that has an
undetectable VL). Specificity, sensitivity, NPV and PPV were determined for PRL and PR
from70% to100%. With logistic regression analyses, independent risk factors for non-
adherence calculated with PRL were determined. Risk factors for self-reported non-adherence
within this patient population were previously reported [11]. Cut off values for pharmacy refill
data adherence were set at 95% and 80%. The 95% cut off value is the gold-standard threshold
for older cART regimens, the 80% cut off value is based on a study showing that this threshold
appears sufficient to maintain virologic suppression with newer cART regimens [16]. Variables
included in the analyses were: VL, gender, region of origin, sexual orientation, family situation,
marital status, educational attainment, employment status, alcohol and substance use, social
support, HIV-related stigma, treatment adherence self-efficacy, and physical and mental qual-
ity of life [11]. For these analyses, scores from the psychosocial variables (social support, inter-
nalized HIV-related stigma, treatment adherence self-efficacy, and physical and mental quality
of life) were dichotomized based on their median values. In multivariable analysis, we submit-
ted all variables demonstrating a P<0.15 in the univariable analyses.
Results
Patient population
In total, 301 MPLWH used cART for>6 months at inclusion. Of these patients two withdrew
their informed consent for contacting their pharmacy, thus 299 patients were included. About
57% were male (n = 112), mean age was 43.2 (SD 10.2) and mean of years on cART was 4.5
(SD 3.3) (Table 1).The majority of the population originated from Sub Saharan Africa region
(42.1%). Most of the patients were heterosexual (65.2%), lived with family (39.5%) and were
Adherence in HIV-infected migrants
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Table 1. Patient characteristics.
Total Complete pharmacy data Incomplete pharmacy data P
Variable n = 299 n = 196 n = 103
Male (%) 171 (57.2) 112 (57.1) 59 (57.3) 0.98c
Age (mean, SD) 43.2 (10.2) 44.9 (9.5) 39.9 (10.9) <0.001d
Years on cART (mean, SD) 4.50 (3.3) 5 (3.3) 3.5 (3.1) <0.001d
cART regimen (%) <0.05e
NRTI+NNRTI 197 (65.9) 132 (67.3) 65 (63.1)
NRTI+PI 87 (29.1) 50 (25.5) 37 (35.9)
NRTI+NNRTI+PI 5 (1.7) 4 (2.0) 1 (1.0)
Othera 10 (3.3) 10 (5.1) 0
Region of origin (%) 0.84c
Sub Saharan Africa 126 (42.1) 83 (42.3) 43 (41.7)
The Caribbean 62 (20.7) 38 (19.4) 24 (23.3)
Latin America 59 (19.7) 39 (19.9) 20 (19.4)
Other 52 (17.4) 36 (18.4) 16 (15.5)
Sexual orientation (%) 0.74c
Heterosexual 195 (65.2) 130 (66.3) 65 (63.1)
Homosexual/Bisexual 93 (31.1) 59 (30.1) 34 (33.0)
Doesn’t know 8 (2.7) 6 (3.1) 2 (1.9)
Missing data 3 (1.0) 1 (0.5) 2 (1.9)
Family situation (%) 0.08c
Lives alone 110 (36.8) 76 (38.8) 34 (33.0)
Single parent 49 (16.4) 31 (15.8) 18 (17.5)
Lives with family (parents, partner, kids) 118 (39.5) 80 (40.8) 38 (36.9)
Other 22 (7.4) 9 (4.6) 13 (12.6)
Marital status (%) 0.57c
Unmarried 179 (58.9) 113 (57.7) 63 (61.2)
Married/registered partnership 68 (22.7) 49 (25.0) 19 (18.4)
Divorced 45 (15.1) 28 (14.3) 17 (16.5)
Widow/Widower 9 (3.0) 5 (2.6) 4 (3.9)
Missing data 1 (0.3) 1 (0.5) 0
Education (%) 0.58c
No formal/Primary school 79 (26.4) 51 (26.0) 28 (27.2)
Secondary school 94 (31.4) 61 (31.1) 33 (32.0)
Higher vocational school 66 (22.1) 40 (20.4) 26 (25.2)
University 58 (19.4) 42 (21.4) 16 (15.5)
Missing data 2 (0.7) 2 (1.0)
Employment (%) 0.19c
Paid job/Self-employed 119 (39.8) 83 (42.3) 36 (35.0)
Unemployed/Looking for a job 82 (27.4) 50 (25.5) 32 (31.1)
Sick/Unable to work 33 (11.0) 25 (12.8) 8 (7.8)
Other 65 (21.7) 38 (19.4) 27 (26.2)
Alcohol and substance use (%)
Alcohol use in past 30 days 163 (54.5) 107 (54.6) 56 (54.4) 0.88c
Missing data 2 (1.9)
Substance use in past 30 days 49 (16.4) 30 (15.3) 19 (18.4) 0.44c
Missing data 2 (1.9)
CD4-Count (10^6/L) (median, IQR) 550.0 (420–710) 570 (440–720) 540 (350–680) 0.11f
VL (%)
(Continued )
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unmarried (58.9%). Median CD4+ cell count was 55010^6/L (IQR 420.0–710.0) and 11% had
a detectable VL.
Of the 299 patients, 245 provided one pharmacy address, 39 provided two pharmacy
addresses, and four provided three pharmacy addresses. Patient pharmacies were unknown
for 11 of the participants, because they could not remember the name of their pharmacy or
were not known at the pharmacy that they had indicated. Pharmacies did not respond to
repeated requests for data for 24 patients. For 31 patients data could not be used, for instance
because medication was delivered at home. Of the remaining 233 patients, data about leftover
medication was not available for 37, leaving for a total of 196 patients with complete data.
These 196 patients (complete data, CD) were significantly older (44.9 years, SD 9.5) than
the 103 of whom the pharmacy refill data could not be fully retrieved (ID) (39.9 years, SD 10.9)
(Table 1). In addition, the mean number of years on cART was significantly higher in the CD
group (5 years) compared to the ID group (3.5 years). Regimens containing nucleoside reverse
transcriptase inhibitors (NRTI’s) plus protease inhibitors (PI’s) were used less frequently in the
CD group (25.5%) compared to the ID group (35.9%). Furthermore, patients in the CD group
originated less often from the Caribbean (19.4% versus 23.3%). The two groups did not differ
significantly in self-reported adherence percentages.
Table 1. (Continued)
Total Complete pharmacy data Incomplete pharmacy data P
Variable n = 299 n = 196 n = 103
HIV-1 297 (99.3) 195 (99.5) 102 (99.0) 0.64c
Detectableb 33 (11.0) 19 (9.7) 14 (13.6) 0.31c
Self-reported adherence (%) 0.92c
Adherent 139 (46.5) 92 (46.9) 47 (45.6)
Non-adherent 157 (52.5) 103 (52.6) 54 (52.4)
Missing data 3 (1.0) 1 (0.5) 2 (1.9)
Psychosocial variables (median, IQR)
Social support 75.0 (42.2–90.6) 75.0 (40.6–87.5) 75.0 (43.8–93.8) 0.53f
Missing data 18 (6.0) 12 (6.1) 6 (5.8)
Stigma 15.0 (12.0–18.0) 15.0 (12.0–18.8) 14.0 (12.0–18.0) 0.38f
Missing data 15 (5.0) 8 (4.1) 7 (6.8)
Self-efficacy 8.8 (7.7–9.7) 8.9 (7.8–9.8) 8.8 (7.4–9.6) 0.31f
Missing data 50 (16.7) 3 (17.3) 16 (15.5)
Quality of life (QoL)
Physical QoL 52.3 (41.3–56.2) 52.5 (41.2–56.2) 51.3 (42.3–55.6) 0.89f
Missing data 8 (2.7) 4 (2.0) 4 (3.9)
Mental QoL 49.4 (39.0–57.3) 49.0 (38.6–57.0) 49.9 (39.4–57.7) 0.80f
Missing data 8 (2.7) 4 (2.0) 4 (3.9)
cART, combination Antiretroviral Therapy; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; INI, integrase inhibitors; NRTI/
NtRTI, nucleoside reverse transcriptase inhibitors/ nucleotide reverse transcriptase inhibitors; VL, viral load; na, not applicable.
a NRTI+INI (2), NNRTI+PI (2), NRTI only (2), PI only (4).
bHIV-1 and HIV-2 > 50 copies/ml
cChi-square
dT-test
eFisher‘s Exact
fMann-Whitney test
https://doi.org/10.1371/journal.pone.0186912.t001
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Adherence using pharmacy refill data and self-reporting
Table 2 shows the number of patients who were classified as adherent with cut off values of
70% to100%, for calculations including leftover medication (PRL), and for calculations
excluding leftover medication (PR). Using a cut off value of100% in the PRL group, 65.8%
was classified as adherent compared to 44.6% in the PR group. Lowering the cut off value
increased the percentage classified as adherent. Specificity was 52.6% for patients with PRL
Table 2. Comparison of adherence measures.
Adherence measure Cutoff value Adherent
N (%)
Sensitivity
(%)
Specificity(%) PPV
(%)
NPV
(%)
OR
(95% CI)
Pharmacy refill adherence when leftover medication in included
(PRL)
N = 196
 100 129
(65.8)
67.8 52.6 93.0 14.9 2.34
(0.90–6.07)
 95 147
(75.0)
77.4 47.4 93.2 18.4 3.08
(1.17–8.11)
 90 154
(78.6)
80.8 42.1 92.9 19.0 3.06
(1.14–8.19)
 85 160
(81.6)
84.2 42.1 93.1 22.2 3.87
(1.43–
10.48)
 80 168
(85.7)
88.7 42.1 93.5 28.6 5.71
(2.05–
15.88)
 75 173
(88.3)
91.0 36.8 93.1 30.4 5.87
(2.03–
17.01)
 70 176
(89.3)
92.1 31.6 92.6 30.0 5.37
(1.77–
16.32)
Pharmacy refill adherence when leftover medication is excluded (PR)
N = 233
 100 104
(44.6)
45.3 61.9 92.3 10.0 1.35
(0.54–3.38)
 95 132
(56.7)
58.0 57.1 93.2 11.9 1.84
(0.74–4.56)
 90 157
(67.4)
68.9 47.6 92.9 13.1 2.01
(0.81–4.97)
 85 168
(72.1)
75.6 42.6 92.6 13.9 2.09
(0.84–5.23)
 80 183
(78.5)
80.2 38.1 92.9 16.0 2.49
(0.97–6.39)
 75 193
(82.8)
84.4 33.3 92.7 17.5 2.71
(1.02–7.23)
 70 198
(85.0)
92.4 28.6 93.7 17.1 2.52
(0.91–7.03)
Self-reported adherence
N = 296
139
(47.0)
49.2 71.9 93.5 14.6 2.48
(1.11–5.56)
Self-reported adherence among patients with PRL
N = 195a
92 (46.9) 49.2 72.2 94.6 12.6 2.51
(0.86–7.35)
Self-reported adherence among patients with PR
N = 232a
109
(46.8)
48.6 70.0 94.5 11.4 2.21
(0.82–5.96)
Sensitivity, percentage of patients with undetectable viral load who are identified as adherent, Specificity, percentage of patients with detectable viral load
who are identified as non-adherent; PPV, positive predictive value, percentage of adherent patients that has an undetectable viral load; NPV, negative
predictive value, percentage of non-adherent patients that has a detectable viral load; PRL, pharmacy refill adherence when left over medication is included;
PR, pharmacy refill adherence when left over medication is not included.
a Self-reported adherence data from 1 participant was missing.
https://doi.org/10.1371/journal.pone.0186912.t002
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100% and decreased with lower adherence cut off values. Higher cut off values had a lower
sensitivity. PPV was around 93% for all cut off values, while NPV increased when lower cut off
values were used.
Using the self-reported adherence questions among the patients who had a self-reported
adherence outcome (n = 296), 139/296 (47.0%) reported to be adherent (Table 2). When only
participants with both a self-reported adherence outcome and a PRL outcome were included
in the analyses, 92/195 (46.9%) reported to be adherent. Compared to the self-reported adher-
ence measure, specificity was lower and sensitivity of the pharmacy refill measure was higher
with decreasing PRL cut off values. There was no significant difference in PPV, and NPV
between PRL using the higher cut off values and self-reported adherence.
Factors associated with non-adherence
Factors associated with<95% pharmacy refill adherence in the univariable analyses were: hav-
ing a detectable VL, having a ‘other’ type of employment status (vs paid employment), having
a low physical quality of life, and having a low mental quality of live (data not shown). Vari-
ables demonstrating a P<0.15 were: experiencing low social support, and high internalized
stigma. Factors associated with<80% pharmacy refill adherence were having a detectable VL,
being on sick leave, having a ‘other’ type of employment status (vs paid employment), drug use
in the previous 30 days, and having a low physical quality of life (data not shown). Being on a
regimen containing a NRTI plus PI (vs a regimen containing NRTI plus NNRTI) demon-
strated a P<0.15.
In the multivariable analyses (Table 3), having a ‘other’ type of employment status (vs paid
employment), a low physical quality of life, and a low mental quality of life were marginally
significantly associated with <95% pharmacy refill adherence (P<0.10). Having a detectable
VL persisted to be significantly associated to a <80% pharmacy refill adherence, as was being
on sick leave (vs. paid employment. Having an ‘other’ type of employment status (vs paid
employment) was marginally significantly associated with<80% pharmacy refill adherence.
Discussion
The HIV-infected population in many western European countries increasingly consists of
migrants from countries where HIV-infection is highly prevalent. Practical methods to assess
adherence in this population are needed as migrants are at risk of having a lower adherence
and suboptimal virological response. Our study demonstrates that pharmacy refill adherence
and four self-report adherence questions, can predict undetectable VL. Self-reported adher-
ence questions have higher specificity and lower sensitivity compared to PRL. PPV and NPV
are similar for both methods. In addition, having an ‘other’ type of employment status is asso-
ciated with <95% and having a detectable VL with 80% pharmacy refill adherence.
HIV-RNA was detectable in 11% of HIV-infected migrants on cART. This percentage of
viremic patients is similar to that found in other studies measuring the association between
adherence and virological failure [21, 22], but is lower than previously found in Dutch
MPLWH [6]. It is not clearly defined what the gold-standard for adherence studies in HIV-
infected patients is. Some studies use pharmacy refill data as golden standard to asses self-
reported adherence [23], but most studies use virologic failure [6, 16, 21, 24]. However, incom-
plete adherence is associated with residual HIV-1 replication, even in the absence of plasma
viremia [25]. Because the clinical goal of treatment with cART is to achieve or maintain unde-
tectable plasma viral load, we compared self-reported- and pharmacy refill adherence in their
ability to predict viral suppression.
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An association between having an ‘other’ type of employment status with<95% pharmacy
refill adherence was found. A total of 38 patients were in this group, of whom 15 were identi-
fied to be<95% adherent. Most reported to be a housewife/-man (n = 7) or student (n = 4).
Being on sick leave was associated with <80% pharmacy refill adherence. A total of 25 were in
this group, of whom 6 were identified to be<80% adherent. A possible reason for these associ-
ations might be a less structured lifestyle, although this remains speculative.
Of the patients showing 100% PRL adherence, 21.2% was misclassified as non-adherent
when leftover medication was not taken into account. This supports the results from another
study where a high percentage was misclassified as non-adherent [13]. Therefore we advise to
include leftover medication from previous refills in future studies calculating adherence to
cART based on pharmacy refill data in countries that do not have a closed pharmacy system.
Defining adherence using pharmacy refill data is challenging. With older cART regimens, a
threshold of 95% has been used in clinical practice. Recently it has been shown that for three
regimens (emtricitabine-tenofovir plus efavirenz or raltegravir or boosted protease inhibitor
(darunavir or atazanavir)) 80% adherence resulted in no more than 3.5% virological failure,
Table 3. Factors related to PRL non-adherencea.
Multivariable Regression <95% PR adherence <80% PR adherence
Variable OR 95% CI P OR 95% CI P
cART regime
NRTI+NNRTI 1
NRTI+PI 1.16 0.42–3.21 0.78
NRTI+NNRTI+PI 0.75 0.06–10.37 0.83
Other 0 0 0.99
HIV-RNA
<50 copies/ml 1 1
>50 copies/ml 2.72 0.83–8.91 0.99 4.94 1.42–17.23 <0.05
Employment status
Paid employment 1 1
Unemployed 1.34 0.45–3.95 0.60 2.09 0.58–7.60 0.26
On sick leave 1.92 0.54–6.78 0.31 4.76 1.10–20.66 <0.05
Other 3.53 1.23–10.11 <0.05 3.41 0.89–13.06 0.07
Drugs use < 30 days
No 1
Yes 2.31 0.79–6.76 0.13
Social support
High social support 1
Low social support 1.28 0.56–2.92 0.56
Internalized HIV-related stigma
Low internalized stigma 1
High internalized stigma 1.56 0.71–3.43 0.27
Quality of life
High physical QoL 1 1
Low physical QoL 2.26 0.97–5.23 0.06 1.54 0.57–4.14 0.40
High mental QoL 1
Low mental QoL 1.82 0.93–3.57 0.08
Educ, Education; Prim, Primary; QoL, Quality of Life.
aAll variables with a P<0.15 in the univariable analyses were submitted in multivariable analyses.
https://doi.org/10.1371/journal.pone.0186912.t003
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whereas adherence of>90% resulted in 1.1% virological failure [16]. The majority of our
patients (n = 284, 95%) used a nucleoside reverse transcriptase inhibitor (NRTI) plus a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) (Table 1) and
our results support the suggestion that a pharmacy refill adherence of 80–90% might be suffi-
cient to maintain virologic suppression with the newer cART regimens.
Self-reported adherence is a cheap and easy way to measure adherence. Self-reported adher-
ence using elaborate questionnaires with over 19 items has been shown to predict virological
suppression in HIV-patients in high resource settings [6, 16]. In low resource settings, self-
reported adherence questions similar to those used in the present study were reported to pre-
dict detectable viral load [14]. However, a questionnaire with a visual analog score scale for
missed doses and 2 questions regarding missed doses [26] was found to be inferior to phar-
macy refill data in predicting virologic failure [22]. Little is known about the validity of self-
reported adherence among migrant populations. Self-reported adherence may be biased due
to cultural differences or language barriers. Using different questionnaires for adherence,
migrants using cART showed a tendency to provide more socially desirable answers [6]. Social
desirability bias could even be more pronounced if adherence questions are administered dur-
ing face-to-face interviews due to literacy problems. However, using a 4-item questionnaire,
we show that self-reported adherence predicts virologic suppression in MPLWH treated in a
high resource setting. In MPLWH the 4-item questionnaire seems an easy way to identify
non-adherent patients and to further determine adherence and barriers to adherence.
The strength of our study is that it is a real life study involving MPLWH using cART during
a wide range of time. Our results may be extrapolated to similar clinical settings. Our study
should be viewed in the context of some limitations. We measured adherence, but not the bar-
riers to adherence. In an analysis of 11 AIDS Clinical Trials Group studies it was shown that
patients reporting a higher number of adherence barriers had lower odds of attaining virologic
suppression [27]. The most commonly mentioned adherence barriers were being away from
home or forgetting to take the pills. Adherence barriers may differ between different HIV-
infected populations. In MPLWH, internalized stigma was associated with non-adherence
[10]. Therefore, after identification of MPLWH that are non-adherent, barriers should be
assessed to start successful interventions. Another limitation is that we did not evaluate
whether non-adherence is associated with the use of certain cART regimens. However, most
patients in the Netherlands, including migrants, use the newer cART regimens and since we
wanted to study our adherence measures in real life, we choose not to break the results down
to the different cART regimens.
In conclusion, in MPLWH both methods, PRL and self-reported adherence questions, can
predict undetectable VL. Using self-reported adherence questions results in a lower sensitivity
and a higher specificity compared to PRL. PPV and NPV are similar for both methods. Col-
lecting PRL of MPLWH in a country with no closed pharmacy system is laborious and not
possible for all patients. This study shows that using four items in self-reported adherence is
sufficient to predict adherence which is crucial for optimal clinical outcome in HIV-infected
migrants.
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